{'fraction_non_alphanumeric': 0.02053915275994865, 'fraction_numerical': 0.0, 'mean_word_length': 5.782608695652174, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Troglitazone prevents fatty changes of the liver in obese diabetic rats

Abstract Background and Aims: Troglitazone is a newly developed antidiabetic drug and is indicated to be useful for the treatment of patients with type II diabetes mellitus. Recently, however, it became clear that troglitazone could cause liver dysfunction in some patients. In addition, a relationship between the activation of the peroxisome proliferator‐activated receptor gamma receptor by troglitazone and colon tumorigenesis has been suggested. The present study was undertaken to examine the effects of long‐term administration of troglitazone on the liver and intestine in genetically obese and diabetic Otsuka Long‐Evans Tokushima Fatty (OLETF) and control Long‐Evans Tokushima Otsuka (LETO) rats.